ReviewThe Journal of clinical investigation2017
Role of steroid receptor and coregulator mutations in hormone-dependent cancers.
Review in The Journal of clinical investigation, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 46 citations in OpenAlex.
- Identification of ETV4 as a prognostic biomarker and correlates with immune cell infiltration in head and neck squamous cell carcinoma.Scientific reports · 2025Article
- Long-range gene regulation in hormone-dependent cancer.Nature reviews. Cancer · 2023Review
- Celastrol recruits UBE3A to recognize and degrade the DNA binding domain of steroid receptors.Oncogene · 2022Article
- Thyroid Diseases and Breast Cancer.Journal of personalized medicine · 2022Review
- Article
- Individual-specific functional epigenomics reveals genetic determinants of adverse metabolic effects of glucocorticoids.Cell metabolism · 2021Article
- Genome-wide crosstalk between steroid receptors in breast and prostate cancers.Endocrine-related cancer · 2021Review
- Review
- Mechanisms of enhancer action: the known and the unknown.Genome biology · 2021Review
- A Positive Feedback Loop Between TGFβ and Androgen Receptor Supports Triple-negative Breast Cancer Anoikis Resistance.Endocrinology · 2021Article
- Article
- X- and Y-Linked Chromatin-Modifying Genes as Regulators of Sex-Specific Cancer Incidence and Prognosis.Clinical cancer research : an official journal of the American Association for Cancer Research · 2020Review
- FOXA1 Mutations Reveal Distinct Chromatin Profiles and Influence Therapeutic Response in Breast Cancer.Cancer cell · 2020Article
- Overcoming Endocrine Resistance in Breast Cancer.Cancer cell · 2020Review
- TXNDC9 regulates oxidative stress-induced androgen receptor signaling to promote prostate cancer progression.Oncogene · 2020Article
- Androgens Induce Invasiveness of Triple Negative Breast Cancer Cells Through AR/Src/PI3-K Complex Assembly.Scientific reports · 2019Article
- Steroid Receptor Signallings as Targets for Resveratrol Actions in Breast and Prostate Cancer.International journal of molecular sciences · 2019Review
- Tumor-Associated Macrophages Induce Endocrine Therapy Resistance in ER+ Breast Cancer Cells.Cancers · 2019Article
- PELP1 Suppression Inhibits Gastric Cancer Through Downregulation of c-Src-PI3K-ERK Pathway.Frontiers in oncology · 2019Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
Abstract
Steroid hormones mediate critical lineage-specific developmental and physiologic responses. They function by binding their cognate receptors, which are transcription factors that drive specific gene expression programs. The requirement of most prostate cancers for androgen and most breast cancers for estrogen has led to the development of endocrine therapies that block the action of these hormones in these tumors. While initial endocrine interventions are successful, resistance to therapy often arises. We will review how steroid receptor-dependent genomic signaling is affected by genetic alterations in endocrine therapy resistance. The detailed understanding of these interactions will not only provide improved treatment options to overcome resistance, but, in the future, will also be the basis for implementing precision cancer medicine approaches.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.